- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Overview
This bill would require the federal government to maintain stricter safety protocols for mifepristone (the abortion pill) by reinstating a previously approved risk evaluation and mitigation strategy.
Law Today
The FDA currently oversees mifepristone (a medication used to terminate pregnancy) under a risk evaluation and mitigation strategy (REMS) that was modified in 2023 to expand access, including allowing mail distribution and use beyond 10 weeks of gestation in certain circumstances.
If Passed
This bill would require the Secretary of Health and Human Services to reinstate the previous, more restrictive REMS for mifepristone—reverting to requirements that likely include in-person dispensing and narrower availability windows.
AI-generated from the bill text — verify against the official text.
Should I support this?
- Strongly Oppose
- Likely Oppose
- Neutral
- This billLikely Support
- Strongly Support
Likely Support
For Christian parents who hold that life begins at conception and should be legally protected, this bill would reinstate restrictions on an abortion drug, aligning with pro-life convictions. It does not directly burden parental rights or religious freedom in education or conscience; rather, it moves abortion law in a direction many conservative Christian families support on sanctity-of-life grounds.
AI assessment using F3’s editorial criteria — faith, family, and freedom. This is F3’s policy judgment; verify the provisions in the official bill text.
Likely supporters & opponents
Likely support
- Pro-life organizations and advocates — Tighter restrictions on abortion medication protect unborn life and restore safeguards they view as medically and ethically necessary.
- Religious-liberty and conservative family organizations — Limiting access to abortion drugs aligns with their conviction that life begins at conception and should be protected by law.
Likely opposition
- Abortion-access advocates and reproductive-rights organizations — Reinstating restrictive REMS limits women's access to a safe, FDA-approved medication and rolls back gains in reproductive autonomy.
- Medical associations and healthcare providers — Stricter REMS requirements contradict medical evidence and expert guidance on safe mifepristone use and obstruct physician judgment.
AI-inferred typical positions based on the bill’s substance — general stakeholder categories, not confirmed endorsements.
Official summary
To require the Secretary of Health and Human Services to approve a risk evaluation and mitigation strategy for mifepristone that is identical to the strategy previously approved, and for other purposes.
Sponsors
- Mary Miller (R)
- Barry Moore (R)
- Sheri Biggs (R)
- Randy Weber (R)
- Pat Harrigan (R)
- Tim Burchett (R)
- Doug LaMalfa (R)
- Michael Guest (R)
- Andy Harris (R)
Status timeline
- 2025-09-30Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.H
- 2025-09-30Introduced in HouseH
H = House · S = Senate · A = Assembly